BBS Faculty Member - Jarrod Marto

Jarrod Marto

Department of Biological Chemistry and Molecular Pharmacology

Dana-Farber Cancer Institute
Smith Building, Room 1158A
44 Binney Street
Boston, MA 02115
Tel: 617-632-3150
Fax: 617-582-7737
Email: jarrod_marto@dfci.harvard.edu



Our lab is focused on development and application of proteomics-based methods for in-depth analysis of key molecular events in tumorogenesis. Given the highly dynamic nature of biological processes, we are particularly interested in novel and robust strategies for measuring relative changes in both protein expression levels and post-translational modification state of the proteome in response to perturbation. Limited dynamic range is a common obstacle encountered during proteomics-driven analyses of complex mixtures; often times, changes in low abundance proteins are critical to an observed phenotype but are undetectable by proteomics experiments performed in the context of a given biological milieu. We are pursuing a number of different strategies to overcome this hurdle, including: 1.) enrichment of protein classes of interest, either through isolation of cell compartments, or chromatographic- and affinity-based methods; 2.) improved mass spectrometry technology, through internal efforts and via industrial collaboration; 3.) development of novel data processing and bioinformatics algorithms to more efficiently analyze the vast quantity of data generated in global proteomics experiments.

We currently use cell lines as model systems to query relative protein expression and phosphorylation events critical to aberrant signaling, blocked differentiation, and other functional hallmarks of cancer. In principle proteomics-based methods provide a highly parallel readout of multiple biologically relevant events in a single experiment. Collectively these data provide a detailed view of key molecular mechanisms in cancer initiation and progression and can also facilitate drug target discovery and improved characterization of small molecule-based therapeutics. In the future we expect to leverage continued improvements in proteomics methods, in combination with other “-omics” technologies, to transition into analysis of clinical samples and development of new diagnostic protocols to better detect and characterize cancer onset and progression.



Last Update: 8/22/2013



Publications

For a complete listing of publications click here.

 


 

Kao H, Marto JA, Hoffman TL, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn, OJ. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001;194:1313-23.

Lippolis JD, White FM, Marto JA, Luckey CJ, Bullock TN, Shabanowitz J, Hunt DF, Engelhard VH. Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets. J Immunol 2002;169:5089-97.

Zarling AL, Luckey CJ, Marto JA, White FM, Brame CJ, Evans AM, Lehner PJ, Cresswell P, Shabanowitz J, Hunt DF, Engelhard VH. Tapasin is a facilitator, not an editor, of class I MHC peptide bonding. J Immunol 2003;171:5287-95.

Syka JEP, Marto JA, Bai DL, Horning S, Senko MW, Schwartz JC, Ueberheide B, Garcia B, Busby S, Muratore T, Shabanowitz J, Hunt DF. Novel linear quadrupole ion trap/FT mass spectrometer: performance characterization and use in the comparative analysis of histone H3 post-translational modifications. J Proteome Res 2004;3:621-6.



© 2013 by the President and Fellows of Harvard College